This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Oncolytics Biotech (ONCY), Stryker (SYK) and Alkermes (ALKS)

Tipranks - Tipranks - Fri Jun 19, 8:46AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Oncolytics Biotech (ONCY), Stryker (SYK) and Alkermes (ALKS).

Claim 55% Off TipRanks

Oncolytics Biotech (ONCY)

JonesTrading analyst Boris Peaker maintained a Hold rating on Oncolytics Biotech today. The company’s shares closed last Thursday at $0.97.

According to TipRanks.com, Peaker is a 5-star analyst with an average return of 21.6% and a 46.5% success rate. Peaker covers the Healthcare sector, focusing on stocks such as Adlai Nortye Ltd. Sponsored ADR, ArriVent BioPharma, Inc., and Bicara Therapeutics Inc. ;'>

Oncolytics Biotech has an analyst consensus of Strong Buy, with a price target consensus of $6.00, implying a 544.5% upside from current levels. In a report issued on June 3, TipRanks – PerPlexity also reiterated a Hold rating on the stock with a $1.00 price target.

See the top stocks recommended by analysts >>

Stryker (SYK)

In a report released today, Matthew Taylor from Jefferies maintained a Buy rating on Stryker, with a price target of $455.00. The company’s shares closed last Thursday at $303.74.

According to TipRanks.com, Taylor is a 4-star analyst with an average return of 6.5% and a 54.3% success rate. Taylor covers the Healthcare sector, focusing on stocks such as Edwards Lifesciences, Abbott Laboratories, and Boston Scientific. ;'>

Stryker has an analyst consensus of Strong Buy, with a price target consensus of $388.25, representing a 28.9% upside. In a report issued on June 12, Bank of America Securities also reiterated a Buy rating on the stock with a $380.00 price target.

Alkermes (ALKS)

Jefferies analyst Akash Tewari maintained a Buy rating on Alkermes today and set a price target of $59.00. The company’s shares closed last Thursday at $45.03.

According to TipRanks.com, Tewari is a 5-star analyst with an average return of 12.9% and a 57.2% success rate. Tewari covers the Healthcare sector, focusing on stocks such as BioMarin Pharmaceutical, Ionis Pharmaceuticals, and Spyre Therapeutics. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Alkermes with a $48.64 average price target, a 9.3% upside from current levels. In a report issued on June 15, TipRanks – PerPlexity also upgraded the stock to Buy with a $49.00 price target.

Read More on ONCY:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).